RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Very difficult to be constructive There's a lot more information we would all like to know. That doesn't mean we are going to see any of it. Based on how this company operates it's safe to say we will get less information than anyone expects. I think you're setting yourself up for major disappointment if you think you're getting much more than just the MTD
SPCEO1 wrote: If we do not hear a lot more than that, it would be pretty disappointing. Obviously, they will have quite a bit of data onthe way the drug worked and clearly, we want to hear about any indication that the drug made it into the cancer cells, avoided the efflux pump and did its work on killing those cells. If we get that proof of concept, then the door is wide open to so many possibilities it will be pretty exciting. We want to know more about the adverse events they mentioned at the 420mg level - how serious were they and were they caused by docetaxel or the peptide? What will be the dosing schedule in phase 1b - same three week cycle or more often to take advantage of TH-1902's ability to dose more frequently? How many cycles will they pursue. How long until they should see tumor regression in the early patients in the trial and will they announce that as it is seen. I could go on, but there is a lot we would like to know.
jeffm34 wrote: What results are you expecting from the the phase 1a? The only results they will announce will be the dose they are using in the phase 1b trial. They've already said that will be 300mg barring any major change in findings.
SPCEO1 wrote: Obviously, the timing is hard too as we should be hearing about the phase 1a results right around the time of the AGM